GIST基因突變檢測試劑盒市場規模、佔有率和成長分析：按技術、突變類型、最終用戶、應用和地區分類－2026-2033年產業預測

2024 年全球 GIST 基因突變檢測試劑盒市場價值為 4.78 億美元，預計到 2033 年將從 2025 年的 5.2915 億美元成長到 11.9332 億美元，預測期（2026-2033 年）的複合年成長率為 10.7%。

全球胃腸道基質腫瘤（GIST）基因突變檢測試劑盒市場專注於檢測GIST中KIT和PDGFRA基因突變的分子診斷，從而實現個人化治療方案。該技術能夠將合適的蛋白酪氨酸激酶抑制劑與患者合併使用，改善治療效果，提高存活率，並最大限度地減少不必要的副作用。隨著精準腫瘤學的發展，腫瘤科醫師越來越需要在診斷時進行分子譜分析，這推動了對這些試劑盒的需求。此外，包括GIST檢測在內的次世代定序技術正在不斷整合，不僅能夠進行更廣泛的突變分析，還能降低成本。隨著醫療機構向多重檢測平台轉型，對高度適應性強的GIST檢測解決方案的需求預計將會增加，這將吸引研發投資，並為創新企業拓展市場機會。

全球胃腸道間質瘤基因突變檢測試劑盒市場的成長要素

腫瘤精準醫療的日益普及促使檢查室尋求高效的突變檢測解決方案。這一趨勢推動了對胃腸道間質瘤（GIST）檢測試劑盒的需求，這些試劑盒能夠快速、同步地分析具有臨床意義的突變，從而拓展個人化治療方案，並在各種醫療環境中改善患者的治療效果。此外，這些試劑盒簡化了檢測開發流程，縮短了結果報告時間，並幫助檢查室滿足新的生物標記指南的要求。綜上所述，這些優勢凸顯了將這些先進技術整合到研究和診斷中的戰略重要性，從而確保在全球醫療保健領域創造永續的價值。

全球胃腸道間質瘤基因突變檢測試劑盒市場的限制因素

先進的胃腸道間質瘤（GIST）基因突變檢測試劑盒高成本，是其推廣應用的主要障礙，尤其是在小規模檢查室和新興市場。預算限制迫使這些機構優先購買必要的試劑而非昂貴的專業檢測，從而延緩了創新解決方案的採用，或迫使他們選擇功能較為有限的方案。這種趨勢阻礙了尖端技術在市場上的整體普及，並可能抑制其成長潛力，儘管科學不斷進步。此外，保險報銷政策的不確定性也抑制了對這些新型試劑盒的投資，導致醫療機構繼續遵循現有的調查方法，而不是探索新的改進途徑。

全球胃腸道間質瘤基因突變檢測試劑盒市場趨勢

全球胃腸道間質瘤（GIST）基因突變檢測試劑盒市場正經歷一個主要趨勢，而這一趨勢的驅動力正是精準腫瘤學方案的整合。隨著醫療機構擴大採用全面的基因組分析，能夠基於特定腫瘤特徵實現個人化治療的GIST基因突變檢測試劑盒的需求也日益成長。這項轉變與製藥公司致力於識別適合標靶治療試驗的患者群體、提高治療效果並最大限度減少副作用的努力不謀而合。因此，合作研究網路和真實世界數據（REW）的累積進一步提升了這些診斷工具的臨床意義，並鞏固了它們在推動以患者為中心的腫瘤治療中的作用。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球胃腸道間質瘤基因突變檢測試劑盒市場規模：依技術分類

• 基於PCR的試劑盒
• 次世代定序（NGS）試劑盒
• Sanger定序盒
• 其他分子技術

全球胃腸道間質瘤基因突變檢測試劑盒市場規模：按突變類型分類

• KIT基因突變檢測
• PDGFRA基因突變檢測
• 多基因突變的檢測

全球胃腸道間質瘤基因突變檢測試劑盒市場規模：依最終用戶分類

• 醫院
• 診斷檢查室
• 癌症研究機構
• 製藥和生物技術公司

全球胃腸道間質瘤基因突變檢測試劑盒市場規模：按應用領域分類

• 臨床診斷
• 治療方案
• 出於研究目的

全球胃腸道間質瘤基因突變檢測試劑盒市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd.
• QIAGEN NV
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Illumina, Inc.
• Danaher Corporation
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• Guardant Health, Inc.
• Myriad Genetics, Inc.
• NeoGenomics, Inc.
• Natera, Inc.
• GenScript Biotech Corporation
• BGI Genomics Co., Ltd.
• Sysmex Corporation
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Integrated DNA Technologies, Inc.
• Invivoscribe, Inc.
• Biocartis Group NV

結論與建議

Global Gist Mutation Detection Kit Market size was valued at USD 478.0 Million in 2024 and is poised to grow from USD 529.15 Million in 2025 to USD 1193.32 Million by 2033, growing at a CAGR of 10.7% during the forecast period (2026-2033).

The global market for GIST mutation detection kits focuses on molecular diagnostics that detect KIT and PDGFRA mutations in gastrointestinal stromal tumors, facilitating personalized therapy choices. This capability enhances patient outcomes by pairing them with appropriate tyrosine-kinase inhibitors, thus improving survival rates and minimizing unnecessary side effects. The shift towards precision oncology is driving demand for these kits, as oncologists are increasingly required to conduct molecular profiling at diagnosis. Additionally, the integration of next-gen sequencing panels that include GIST assays is gaining traction, offering a broader mutation analysis while reducing costs. As healthcare facilities transition towards multiplex platforms, the demand for adaptable GIST detection solutions is projected to rise, attracting R&D investments and expanding market opportunities for innovative players.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gist Mutation Detection Kit market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gist Mutation Detection Kit Market Segments Analysis

Global gist mutation detection kit market is segmented by technology, mutation type, end user, application and region. Based on technology, the market is segmented into PCR-based kits, next-generation sequencing (NGS) kits, sanger sequencing kits and other molecular technologies. Based on mutation type, the market is segmented into KIT gene mutation detection, PDGFRA gene mutation detection and multi-gene mutation detection. Based on end user, the market is segmented into hospitals, diagnostic laboratories, cancer research institutes and pharmaceutical & biotechnology companies. Based on application, the market is segmented into clinical diagnosis, treatment selection and research use. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gist Mutation Detection Kit Market

The growing adoption of precision medicine within oncology practices is motivating laboratories to pursue effective mutation detection solutions. This trend is leading to a heightened demand for GIST kits, which allow for rapid and simultaneous analysis of clinically significant mutations, thereby enhancing personalized treatment choices and boosting patient outcomes across various healthcare environments. Furthermore, these kits simplify the assay development process, decrease turnaround times, and help laboratories meet new biomarker guidelines. Collectively, these advantages emphasize the strategic importance of integrating such advanced technologies in both research and diagnostic settings, ensuring sustained value within the global healthcare landscape.

Restraints in the Global Gist Mutation Detection Kit Market

The elevated costs associated with advanced GIST mutation detection kits pose a significant barrier to accessibility, particularly for smaller laboratories and emerging markets. Budgetary limitations often lead these institutions to prioritize essential reagents over expensive specialized tests, forcing them to postpone the adoption of innovative solutions or choose less comprehensive options. This tendency can hinder the overall penetration of advanced technologies within the market, stunting growth potential despite ongoing scientific progress. Furthermore, uncertainties regarding reimbursement policies deter investment in these novel kits, prompting healthcare providers to continue with their existing methodologies rather than exploring new avenues for improvement.

Market Trends of the Global Gist Mutation Detection Kit Market

The Global GIST Mutation Detection Kit market is witnessing a significant trend driven by the integration of precision oncology protocols. As healthcare providers increasingly adopt comprehensive genomic profiling, there is a growing demand for GIST mutation detection kits that enable the customization of therapies based on specific tumor signatures. This shift not only enhances treatment efficacy and minimizes adverse effects but also aligns with pharmaceutical companies' efforts to identify optimal patient groups for targeted trials. Consequently, collaborative research networks and the production of real-world evidence further propel the clinical relevance of these diagnostic tools, solidifying their role in advancing patient-centric oncology care.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global GIST Mutation Detection Kit Market Size by Technology & CAGR (2026-2033)

• Market Overview
• PCR-Based Kits
• Next-Generation Sequencing (NGS) Kits
• Sanger Sequencing Kits
• Other Molecular Technologies

Global GIST Mutation Detection Kit Market Size by Mutation Type & CAGR (2026-2033)

• Market Overview
• KIT Gene Mutation Detection
• PDGFRA Gene Mutation Detection
• Multi-Gene Mutation Detection

Global GIST Mutation Detection Kit Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Pharmaceutical & Biotechnology Companies

Global GIST Mutation Detection Kit Market Size by Application & CAGR (2026-2033)

• Market Overview
• Clinical Diagnosis
• Treatment Selection
• Research Use

Global GIST Mutation Detection Kit Market Size & CAGR (2026-2033)

• North America (Technology, Mutation Type, End User, Application)
  • US
  • Canada
• Europe (Technology, Mutation Type, End User, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Mutation Type, End User, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Mutation Type, End User, Application)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Mutation Type, End User, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integrated DNA Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invivoscribe, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocartis Group NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations